|Bid||33.250 x N/A|
|Ask||33.350 x N/A|
|Day's Range||32.700 - 33.800|
|52 Week Range||28.800 - 46.700|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 30, 2021|
|Forward Dividend & Yield||0.08 (0.23%)|
|Ex-Dividend Date||Jun 10, 2021|
|1y Target Est||N/A|
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, and Hansoh Pharmaceutical Group Company Limited ("Hansoh Pharma", 3692:HK), one of the leading biopharmaceutical companies in China, today announced a strategic partnership and license agreement for the development and commercialization of Ibrexafungerp for the Greater China region.
Terns Pharmaceuticals and Hansoh Pharma Announce Collaboration and License Agreement for TRN-000632 in Greater China
First paragraph, fourth sentence of the release should read: Hansoh will receive approximately $100 million in upfront payment and development and regulatory milestones, with additional undisclosed commercial milestones as well as royalty payments (instead of Hansoh will receive undisclosed upfront, regulatory and commercial milestone payments, as well as royalty payments).